Want to see PTCT full AI Analyst Report?
Top Page
PTC Therapeutics
(NASDAQ:PTCT)
Select Model
Select Model
Rating:51Neutral
Price Target:
$68.00
▼(-11.48% Downside)
Action:Reiterated
Date:08/01/26
The score is held back primarily by weakened and volatile financial quality (TTM return to losses and cash burn) and a structurally pressured balance sheet with persistently negative equity. Technicals also detract as the stock is trading below major moving averages. These risks are partially offset by a strong earnings call with raised 2026 revenue guidance and robust Sephience launch traction, which improves the near-term growth outlook despite ongoing legacy product and regulatory-timing headwinds.
Positive Factors
Sephience commercial momentum
Sustained launch traction with accelerating prescriptions, strong refill rates and growing patient counts supports durable, recurring product revenue. Broadening payer coverage and planned expansion to ~30 countries expand addressable market, underpinning multi‑year commercial growth potential (> $2B opportunity).
Negative Factors
Negative shareholders' equity & leverage
A prolonged equity deficit signals cumulative losses and weak retained capital, constraining financial flexibility. Meaningful debt on a negative‑equity base increases refinancing and covenant risk, limits strategic options like acquisitions, and can force reliance on capital markets during adverse conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
Sephience commercial momentum
Sustained launch traction with accelerating prescriptions, strong refill rates and growing patient counts supports durable, recurring product revenue. Broadening payer coverage and planned expansion to ~30 countries expand addressable market, underpinning multi‑year commercial growth potential (> $2B opportunity).
Read all positive factors
PTC Therapeutics Key Performance Indicators (KPIs)
Any
Revenue by Product
Shows how much revenue each product generates, highlighting which products are driving growth and which may need strategic adjustments.
Shows how much revenue each product generates, highlighting which products are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyPTC Therapeutics (PTCT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.68B
Dividend YieldN/A
Average Volume (3M)2.17M
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue Growth-42.84%
EPS Growth-106.21%
CountryUS
Employees991
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.49
Shares Outstanding83,460,800
10 Day Avg. Volume1,083,688
30 Day Avg. Volume2,168,230
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-29.43
Price to Sales (P/S)3.49
P/FCF Ratio14.69
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$98.33Price Target Upside28.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)1.43
Revenue Forecast (FY)$1.18B
PTC Therapeutics Business Overview & Revenue Model
Company Description
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commerciali...
How the Company Makes Money
PTC Therapeutics makes money primarily through (1) net product sales of its commercial therapies in markets where it has commercialization rights, and (2) collaboration-related revenue from strategic partnerships. Product revenue is generated by s...
PTC Therapeutics Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Oct 22, 2026
Earnings Call Sentiment Positive
The call emphasized strong commercial execution and materially positive topline results driven by Sephience (record product revenue, 36% QoQ Sephience growth, raised 2026 guidance), meaningful clinical progress in Huntington's (votoplam) and a defined regulatory plan for vatiquinone — all supported by a healthy balance sheet. Lowlights were largely operational or timing issues in mature products (one‑time Translarna order, Emflaza generic erosion), a modest quarter‑to‑quarter cash decline, and the need for an additional vatiquinone trial which delays NDA plans. Overall, the positives (robust launch, guidance raise, favorable HD data, pipeline momentum) substantially outweigh the manageable challenges.Positive Updates
Record Quarterly Revenue and Strong YoY Growth
Total revenue of $273.0M and total product revenue of $226.0M in Q1 2026, representing a 47% increase in product revenue versus Q1 2025 (Q1 2025 product revenue $153M).
Negative Updates
Mature DMD Franchise Uncertainty and One‑Time Order Impact
DMD franchise revenue totaled $81M in Q1 2026, with Translarna contributing $59M that included a large one‑time government purchase order — indicating some near‑term revenue is non‑recurring and future Translarna demand is unpredictable.
Read all updates
Q1-2026 Updates
Positive
Negative
Record Quarterly Revenue and Strong YoY Growth
Total revenue of $273.0M and total product revenue of $226.0M in Q1 2026, representing a 47% increase in product revenue versus Q1 2025 (Q1 2025 product revenue $153M).
Read all positive updates
Company Guidance
PTC raised 2026 full‑year product revenue guidance to $750–$850 million and now expects total revenue of $1.08–1.18 billion, reflecting a record Q1 with total revenue of $273 million and net product revenue of $226 million (Sephience $125 million, up 36% quarter‑over‑quarter — U.S. $112M, international $13M); management reported 1,244 commercial Sephience patients as of March 31, over 2,200 prescriptions since launch, U.S. prescription starts averaging ~140/month and surpassing 1,500 starts in the quarter, plans for commercial sales in up to 30 countries by year‑end, strong refill rates with low double‑digit discontinuations, Q1 non‑GAAP R&D of $90M and non‑GAAP SG&A of $74M, cash and marketable securities of $1.89B, and reiterated confidence that Sephience can be a multi‑billion (>$2B) global opportunity.PTC Therapeutics Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
26
Negative
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.01B | 1.73B | 806.78M | 937.82M | 698.80M | 538.59M |
| Gross Profit | 828.57M | 1.66B | 749.38M | 872.34M | 654.12M | 506.26M |
| EBITDA | 173.51M | 887.66M | -120.46M | -330.34M | -367.78M | -368.18M |
| Net Income | -38.38M | 682.64M | -363.30M | -626.60M | -559.02M | -523.90M |
Balance Sheet | ||||||
| Total Assets | 3.25B | 2.90B | 1.71B | 1.90B | 1.71B | 1.94B |
| Cash, Cash Equivalents and Short-Term Investments | 2.23B | 1.95B | 1.14B | 876.74M | 410.70M | 773.38M |
| Total Debt | 696.47M | 2.71B | 2.47B | 2.23B | 1.46B | 1.27B |
| Total Liabilities | 3.42B | 3.10B | 2.80B | 2.71B | 2.05B | 1.94B |
| Stockholders Equity | -165.36M | -205.31M | -1.10B | -818.55M | -347.09M | 1.44M |
Cash Flow | ||||||
| Free Cash Flow | -332.56M | 411.18M | -181.94M | -279.04M | -509.11M | -336.66M |
| Operating Cash Flow | -30.50M | 711.20M | -107.69M | -158.42M | -356.65M | -251.33M |
| Investing Cash Flow | -471.91M | -861.98M | 44.18M | -176.74M | 290.18M | 219.18M |
| Financing Cash Flow | 536.00M | 331.09M | 255.87M | 646.40M | 167.95M | 20.88M |
PTC Therapeutics Technical Analysis
Negative
76.82
Price Trends
77.08
Negative
72.94
Negative
73.12
Negative
Market Momentum
-2.19
Positive
28.02
Positive
27.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTCT, the sentiment is Negative. The current price of 76.82 is below the 20-day moving average (MA) of 78.75, below the 50-day MA of 77.08, and above the 200-day MA of 73.12, indicating a bearish trend. The MACD of -2.19 indicates Positive momentum. The RSI at 28.02 is Positive, neither overbought nor oversold. The STOCH value of 27.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PTCT.
PTC Therapeutics Risk Analysis
PTC Therapeutics disclosed 53 risk factors in its most recent earnings report. PTC Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PTC Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $7.96B | 16.36 | 87.36% | ― | 81.26% | 1079.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $5.68B | -137.67 | 21.72% | ― | -42.84% | -106.21% | |
48 Neutral | $7.81B | -7.85 | -32.51% | ― | ― | -71.33% | |
46 Neutral | $4.63B | -7.72 | -30.88% | ― | -89.11% | -37.55% |
* Healthcare Sector Average
PTCT
PTC Therapeutics
68.12
17.00
33.27%
TGTX
TG Therapeutics
46.17
17.77
62.57%
CRSP
Crispr Therapeutics AG
49.57
-6.02
-10.83%
PCVX
Vaxcyte
53.53
19.80
58.70%
PTC Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
PTC Therapeutics Raises Outlook on Strong Q2 Results
Positive
Jul 30, 2026
On July 28, 2026, PTC Therapeutics appointed former Chief Human Resources Officer Hege Sollie-Zetlmayer to its board of directors as a Class III director, filling a vacancy and extending her long-standing leadership role within the company. Her ap...
Business Operations and StrategyPrivate Placements and Financing
PTC Therapeutics Completes Major Convertible Notes Offering
Positive
Jun 18, 2026
On June 18, 2026, PTC Therapeutics completed a private offering of $550 million of 0.0% Convertible Senior Notes due 2031, governed by an indenture with U.S. Bank Trust Company and sold to qualified institutional buyers under Rule 144A. The notes,...
Business Operations and StrategyPrivate Placements and Financing
PTC Therapeutics Prices New 0% Convertible Senior Notes
Positive
Jun 16, 2026
On June 15, 2026, PTC Therapeutics, Inc. priced a private offering of $500 million aggregate principal amount of 0% Convertible Senior Notes due 2031 to qualified institutional buyers under Rule 144A, with an option for initial purchasers to buy a...
Executive/Board Changes
PTC Therapeutics Director Resigns, Moves to Advisory Role
Neutral
Jun 9, 2026
On June 8, 2026, PTC Therapeutics, Inc. announced that board member Alethia Young resigned from the company’s board of directors, citing the need to prioritize other professional commitments and clarifying that her departure did not arise fr...
Executive/Board ChangesShareholder Meetings
PTC Therapeutics Shareholders Back Board, Pay and Auditor
Positive
Jun 5, 2026
PTC Therapeutics reported the results of its June 2, 2026 annual meeting of stockholders, where investors elected four Class I directors, including CEO Matthew B. Klein, M.D., to serve until the 2029 annual meeting or until successors are chosen. ...
Business Operations and StrategyFinancial Disclosures
PTC Therapeutics Lifts 2026 Outlook on Sephience Momentum
Positive
May 7, 2026
On May 7, 2026, PTC Therapeutics reported first-quarter 2026 revenue of $273 million, driven by $226 million in product sales and strong momentum from the global launch of Sephience, which generated $125 million and 36% quarter-over-quarter growth...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.